Data / Research funding / Methamphetamine

Methamphetamine: 243 NIH awards ($440.4M) to 105 organizations

Name: NIH and NSF awards on Methamphetamine
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

243 NIH awards ($440.4M) in the NIH spending category Methamphetamine, to 105 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.

SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.

Get awards on Methamphetamine Watch Methamphetamine

Topic: NIH spending category

Awards

243 awards in the window.

Award	Agency	Institute or division	Fiscal year	Amount in window	Start	End	Principal investigator	Source
NIDA Clinical Trials Network: Big South/West Node (CTN-0132 and CTN-0139)	NIH	National Institute on Drug Abuse	2021 to 2025	$43,417,361	March 1, 2025	February 28, 2032	TRIVEDI, MADHUKAR H.	reporter.nih.gov
The Florida Node Alliance of the National Drug Abuse Clinical Trials Network (CTN-121)	NIH	National Institute on Drug Abuse	2021 to 2025	$26,301,696	March 1, 2025	February 29, 2028	SZAPOCZNIK, JOSE	reporter.nih.gov
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder	NIH	National Institute on Drug Abuse	2021 to 2023	$13,778,020	September 30, 2021	July 31, 2025	STEVENS, MISTY WARD	reporter.nih.gov
AIDS Linked to the IntraVenous Experience (ALIVE) Study	NIH	National Institute on Drug Abuse	2021 to 2025	$12,226,379	January 1, 2014	May 31, 2030	MEHTA, SHRUTI H	reporter.nih.gov
Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication	NIH	National Institute on Drug Abuse	2023 to 2025	$11,962,715	August 15, 2023	June 30, 2026	LI, XINHUA	reporter.nih.gov
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder	NIH	National Institute on Drug Abuse	2022 to 2024	$9,900,251	September 30, 2022	July 31, 2025	STEVENS, MISTY WARD	reporter.nih.gov
M-SCORCH: Methamphetamine use disorder data generation center for Single Cell Opioid Responses in the Context of HIV	NIH	National Institute on Drug Abuse	2021 to 2025	$9,490,616	May 15, 2021	February 28, 2027	HO, YA-CHI	reporter.nih.gov
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder	NIH	National Institute on Drug Abuse	2022 to 2024	$8,683,509	September 30, 2022	July 31, 2025	TOLL, LAWRENCE R	reporter.nih.gov
Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication	NIH	National Institute on Drug Abuse	2021 to 2022	$8,123,947	September 30, 2020	May 31, 2024	LI, XINHUA	reporter.nih.gov
Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD).	NIH	National Institute on Drug Abuse	2024 to 2025	$7,405,564	March 1, 2024	November 30, 2027	DEVARNEY, KATHERINE BEEBE	reporter.nih.gov
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism	NIH	National Institute on Drug Abuse	2021 to 2024	$6,868,774	April 1, 2020	January 31, 2026	STRATHDEE, STEFFANIE A.	reporter.nih.gov
Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder	NIH	National Institute on Drug Abuse	2022	$6,445,203	July 15, 2022	June 30, 2025	COSFORD, NICHOLAS DAVID	reporter.nih.gov
Optimizing HIV prevention for high-risk methamphetamine-using men who have sex with men	NIH	National Institute of Allergy and Infectious Diseases	2024 to 2025	$5,855,396	April 8, 2022	April 30, 2027	GROV, CHRISTIAN	reporter.nih.gov
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)	NIH	National Institute on Drug Abuse	2021 to 2025	$5,664,540	March 1, 2025	February 29, 2032	HATCH, MARY AKIKO	reporter.nih.gov
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS	NIH	National Institute on Drug Abuse	2021 to 2022	$5,613,312	September 30, 2020	June 30, 2024	STEVENS, MISTY WARD	reporter.nih.gov
Preclinical Development of Novel Dual OXR/KOR Antagonists for Treatment of Substance Use Disorder	NIH	National Institute on Drug Abuse	2021	$5,598,515	September 30, 2021	September 29, 2025	BUTERA, JOHN A	reporter.nih.gov
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDS	NIH	National Institute on Drug Abuse	2021 to 2024	$5,321,290	March 1, 2015	April 30, 2026	HAYASHI, KANNA	reporter.nih.gov
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization	NIH	National Institute on Drug Abuse	2021 to 2022	$5,281,643	May 1, 2020	February 29, 2024	STEVENS, MISTY WARD	reporter.nih.gov
Modeling drugs of abuse-HIV interactions using iPSC-derived human cerebral organoids	NIH	National Institute on Drug Abuse	2021 to 2025	$4,890,555	September 30, 2021	July 31, 2026	SANNA, PIETRO P	reporter.nih.gov
Single nucleus gene expression in moderate and compulsive drug self-administration in a rodent model of HIV	NIH	National Institute on Drug Abuse	2022 to 2025	$4,653,858	March 15, 2022	November 30, 2026	SANNA, PIETRO P	reporter.nih.gov
Optimizing HIV prevention for highly vulnerable methamphetamine-using sexual minority men	NIH	National Institute of Allergy and Infectious Diseases	2022 to 2023	$4,518,889	April 8, 2022	April 30, 2024	GROV, CHRISTIAN	reporter.nih.gov
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension	NIH	National Heart, Lung, and Blood Institute	2021 to 2025	$3,677,031	August 20, 2021	May 31, 2027	KAWUT, STEVEN M	reporter.nih.gov
Synthetics in Combination (SYNC)	NIH	National Institute on Drug Abuse	2021 to 2025	$3,536,582	September 30, 2021	June 30, 2026	CICCARONE, DANIEL H	reporter.nih.gov
Promoting remote and secondary risk prevention services in rural settings	NIH	National Institute on Drug Abuse	2022 to 2025	$3,349,340	September 30, 2022	July 31, 2027	PHO, MAI TUYET	reporter.nih.gov
Project Nurture Expansion Study	NIH	Eunice Kennedy Shriver National Institute of Child Health & Human Development	2021 to 2025	$3,304,098	September 24, 2021	August 31, 2026	COHEN, DEBORAH JILL	reporter.nih.gov
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder	NIH	National Institute on Drug Abuse	2025	$3,287,052	May 15, 2025	April 30, 2027	SHIRLEY, RENEE LYNN	reporter.nih.gov
PRIME: PrEP Intervention for people who Inject MEthamphetamine	NIH	National Institute on Drug Abuse	2021 to 2024	$3,225,418	August 1, 2020	June 30, 2026	COFFIN, PHILLIP O	reporter.nih.gov
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse	NIH	National Institute on Drug Abuse	2021 to 2023	$3,182,913	September 30, 2021	August 31, 2024	YOUNG, ERICA J	reporter.nih.gov
A DUAL CHIMERIC HUMAN ASTROGLIAL-MICROGLIAL MODEL OF HIV AND HAND	NIH	National Institute on Drug Abuse	2021 to 2025	$3,125,946	August 1, 2021	May 31, 2026	GOLDMAN, STEVEN ALAN	reporter.nih.gov
Disrupting Social Risk Factors of Health to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions	NIH	National Institute on Drug Abuse	2022 to 2025	$3,001,349	September 1, 2023	August 31, 2027	SALDANA, LISA	reporter.nih.gov
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)	NIH	National Institute on Drug Abuse	2022 to 2024	$2,923,597	July 1, 2023	June 30, 2025	NWAOKOBIA, CHARLES CHIEDU	reporter.nih.gov
Assessing the Reach, Effectiveness, and Implementation of Multiple Interventions	NIH	National Institute on Drug Abuse	2022 to 2025	$2,900,711	September 30, 2022	July 31, 2027	KRAL, ALEXANDER H	reporter.nih.gov
Exploring Influences on Methamphetamine Use Among Males in Georgia	NIH	National Institute on Drug Abuse	2022 to 2025	$2,785,741	June 1, 2022	March 31, 2027	HUSSEN, SOPHIA A.	reporter.nih.gov
Peer Engagement in Methamphetamine Harm-Reduction with Contingency Management (PEER-CM)	NIH	National Institute on Drug Abuse	2022 to 2025	$2,732,822	September 30, 2022	July 31, 2027	KORTHUIS, PHILIP TODD	reporter.nih.gov
Leveraging data synthesis to identify optimal and robust strategies for HIV elimination among substance-using MSM	NIH	National Institute on Drug Abuse	2022 to 2025	$2,637,647	May 1, 2022	February 28, 2027	JANULIS, PATRICK FRANCIS	reporter.nih.gov
Methamphetamine Effect on HIV Persistence	NIH	National Institute on Drug Abuse	2021 to 2024	$2,535,677	July 1, 2020	May 31, 2025	KAUL, MARCUS	reporter.nih.gov
Genomic profiling mediating the protective effect of social reward on opioid craving	NIH	National Institute on Drug Abuse	2022 to 2025	$2,512,064	August 1, 2022	June 30, 2027	VENNIRO, MARCO	reporter.nih.gov
HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral Organoids	NIH	National Institute on Drug Abuse	2021 to 2024	$2,470,488	July 1, 2020	April 30, 2026	HO, WENZHE	reporter.nih.gov
Modeling HIV and methamphetamine-induced neuroinflammation in cerebral organoids	NIH	National Institute on Drug Abuse	2022 to 2025	$2,395,254	September 1, 2022	July 31, 2027	SPEARMAN, PAUL W.	reporter.nih.gov
New targeted BDNF nanoparticles for treatment of METH addiction and neurotoxicity	NIH	National Institute on Drug Abuse	2021 to 2022	$2,378,918	September 1, 2021	August 31, 2025	VITALIANO, FRANCO	reporter.nih.gov
Methamphetamine and Other Substance Use Disorder Genetics in Thailand	NIH	National Institute on Drug Abuse	2023 to 2025	$2,375,708	June 15, 2015	April 30, 2028	GELERNTER, JOEL	reporter.nih.gov
Regulation of HIV latency by microglial-neuronal interactions	NIH	National Institute on Drug Abuse	2021 to 2023	$2,363,459	September 15, 2019	July 31, 2025	KARN, JONATHAN	reporter.nih.gov
Investigating the molecular mechanisms of HIV/AIDS associated neurological disorders using microglia and cerebral organoids derived from induced pluripotent stem cells	NIH	National Institute on Drug Abuse	2021 to 2023	$2,348,133	September 1, 2019	July 31, 2025	RANA, TARIQ M	reporter.nih.gov
Examining the Impact of the Twin Epidemics of Methamphetamine and Opioid Use on Overdose, Risky Sex and Treatment Engagement among PWUD in Two Rural Appalachian Cohorts	NIH	National Institute on Drug Abuse	2021 to 2024	$2,345,140	September 1, 2012	March 31, 2028	HAVENS, JENNIFER R	reporter.nih.gov
In Vivo Imaging and Post-Mortem Study of Methamphetamine Use on Immune Dysfunction and HIV Reservoir Transcription among People with HIV on ART	NIH	National Institute on Drug Abuse	2025	$2,331,737	July 15, 2025	May 31, 2030	HENRICH, TIMOTHY JENSEN	reporter.nih.gov
Computational modeling to evaluate interventions for HIV and substance use	NIH	National Institute on Drug Abuse	2023 to 2025	$2,266,145	September 30, 2023	July 31, 2028	HOTTON, ANNA	reporter.nih.gov
Impact of prescription stimulants on the drug overdose epidemic	NIH	National Institute on Drug Abuse	2023 to 2025	$2,253,245	May 1, 2023	March 31, 2028	DE NADAI, ALESSANDRO STEVENS	reporter.nih.gov
Synthetic Psychoactive "Bath Salt" Effects on Brain Activity and Behavior	NIH	National Institute on Drug Abuse	2021 to 2023	$2,232,449	April 15, 2019	February 28, 2025	KOHUT, STEPHEN JOHN	reporter.nih.gov
Ghrelin Deacylase as a Treatment for Opioid Polysubstance Abuse	NIH	National Institute on Drug Abuse	2022 to 2025	$2,207,625	July 1, 2022	June 30, 2027	ZHAN, CHANG-GUO	reporter.nih.gov
Mirtazapine for methamphetamine use disorder: drug-drug interaction study	NIH	National Institute on Drug Abuse	2021	$2,182,386	June 1, 2020	May 31, 2024	COFFIN, PHILLIP O	reporter.nih.gov
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory	NIH	National Institute on Drug Abuse	2022 to 2024	$2,164,851	December 15, 2019	November 30, 2025	MILLER, COURTNEY A	reporter.nih.gov
Optimizing PrEP adherence in sexual minority men who use stimulants	NIH	National Institute on Drug Abuse	2021 to 2022	$2,152,006	July 1, 2020	July 3, 2023	CARRICO, ADAM WAYNE	reporter.nih.gov
Human/Animal Brain Chimera in drugs of abuse and HIV	NIH	National Institute on Drug Abuse	2022 to 2025	$2,144,306	August 15, 2022	May 31, 2027	AL-HARTHI, LENA	reporter.nih.gov
Comorbidities and other consequences at the intersection of the HIV and substance use epidemics	NIH	National Institute on Drug Abuse	2023 to 2025	$2,110,949	September 1, 2023	June 30, 2028	CRANE, HEIDI M.	reporter.nih.gov
Cerebral organoid and IPSC derived microglia: Modeling of HIV and methamphetamine co-morbidity	NIH	National Institute on Drug Abuse	2022 to 2025	$2,096,889	September 1, 2022	July 31, 2027	YELAMANCHILI, SOWMYA	reporter.nih.gov
New psychoactive substance exposure among NYC nightclub and festival attendees	NIH	National Institute on Drug Abuse	2023 to 2025	$2,051,804	August 15, 2023	May 31, 2027	PALAMAR, JOSEPH J	reporter.nih.gov
Influence of Orexin Antagonism on Opioid and Methamphetamine Demand	NIH	National Institute on Drug Abuse	2023 to 2025	$2,047,388	April 15, 2023	December 1, 2025	STRICKLAND, JUSTIN CHARLES	reporter.nih.gov
Supporting data-driven decision-making to support substance use service expansion policies and to prevent overdoses	NIH	National Institute on Drug Abuse	2024 to 2025	$2,033,987	September 1, 2023	August 31, 2028	CRUDEN, GRACELYN	reporter.nih.gov
Glutamate receptor plasticity underlying incubation of methamphetamine craving	NIH	National Institute on Drug Abuse	2021 to 2025	$2,013,645	September 1, 1996	March 31, 2028	WOLF, MARINA ELIZABETH	reporter.nih.gov
The Role of the Bed Nucleus of the Stria Terminalis-Norepinephrine System in Amphetamine-type Stimulant Use Disorders	NIH	National Institute on Drug Abuse	2023 to 2025	$1,958,010	September 15, 2023	June 30, 2028	PARK, JINWOO	reporter.nih.gov
Effects of HIV-1 Tat protein and methamphetamine on VMAT2-mediated dopamine transmission in the context of neuroHIV and drug abuse	NIH	National Institute on Drug Abuse	2023 to 2025	$1,939,156	April 1, 2023	April 30, 2025	ZHU, JUN	reporter.nih.gov
Relationship between methamphetamine use, viral reservoir dynamics and clinical progression in treated HIV infection	NIH	National Institute on Drug Abuse	2023 to 2025	$1,936,729	June 1, 2023	April 30, 2028	STEVENSON, MARIO	reporter.nih.gov
Methamphetamine, mitochondria, and neurodegeneration	NIH	National Institute on Drug Abuse	2021 to 2025	$1,908,298	April 15, 2021	January 31, 2027	GRAVES, STEVEN MICHAEL	reporter.nih.gov
Determinants of Drug Preference in Humans	NIH	National Institute on Drug Abuse	2021 to 2024	$1,905,360	January 1, 1981	January 31, 2026	DE WIT, HARRIET	reporter.nih.gov
Methamphetamine Effects on Prefrontal Cortical PV+ Interneurons and Resulting Cognitive Deficits	NIH	National Institute on Drug Abuse	2021 to 2025	$1,891,855	September 1, 2021	July 31, 2026	LAVIN, ANTONIETA	reporter.nih.gov
Optimizing PrEP adherence in sexual minority men who use stimulants	NIH	National Institute on Drug Abuse	2023 to 2024	$1,855,864	July 1, 2020	May 31, 2025	CARRICO, ADAM WAYNE	reporter.nih.gov
Screen, Treat and Retain People with Primary Meth Use Disorder at MMT Clinics (STAR-OM+)	NIH	National Institute on Drug Abuse	2021 to 2024	$1,829,872	May 1, 2024	March 31, 2025	LE, GIANG M	reporter.nih.gov
Mining Social Media Big Data for Toxicovigilance: Studying Substance Use via Natural Language Processing and Machine Learning Methods	NIH	National Institute on Drug Abuse	2022 to 2025	$1,773,166	September 30, 2022	July 31, 2027	SARKER, ABEED H	reporter.nih.gov
Systems biology of RNA Modifications in HIV/AIDS and Substance Use Disorders	NIH	National Institute on Drug Abuse	2021 to 2022	$1,760,840	March 15, 2018	December 31, 2023	SANNA, PIETRO P	reporter.nih.gov
Rapid and non-invasive device for drug detection through sweat	NIH	National Institute on Drug Abuse	2022 to 2023	$1,738,402	September 30, 2020	July 31, 2025	KULKARNI, GIRISH	reporter.nih.gov
Methamphetamine injection, associated health risk, and causes of overdose deaths.	NIH	National Institute on Drug Abuse	2022 to 2024	$1,714,422	September 30, 2022	July 31, 2025	KRAL, ALEXANDER H	reporter.nih.gov
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease	NIH	National Institute on Drug Abuse	2024 to 2025	$1,702,671	August 1, 2018	May 31, 2026	LEE, SULGGI ANGELA	reporter.nih.gov
The impact of methamphetamine on CXCL12 mediated HIV neuropathogenesis	NIH	National Institute on Drug Abuse	2022 to 2025	$1,680,000	July 15, 2022	May 31, 2027	BERMAN, JOAN WEINBERGER	reporter.nih.gov
Role of lateral habenula in methamphetamine TAAR1-mediated synaptic plasticity and aversion	NIH	National Institute on Drug Abuse	2023 to 2025	$1,656,889	September 30, 2023	June 30, 2028	INGRAM, SUSAN L	reporter.nih.gov
Development of selective cannabinoid receptor 2 agonists for treatment of addiction	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2025	$1,621,997	April 19, 2022	April 30, 2027	SHAMLOO, MEHRDAD	reporter.nih.gov
Vagus nerve stimulation increases basal dopamine levels in the brain to decrease methamphetamine-mediated responses	NIH	National Institute on Drug Abuse	2023 to 2025	$1,595,645	August 1, 2023	May 31, 2028	KHOSHBOUEI, HABIBEH	reporter.nih.gov
Transgenerational Inheritance of a Cocaine Resistance Phenotype	NIH	National Institute on Drug Abuse	2023 to 2025	$1,594,735	April 1, 2012	January 31, 2027	PIERCE, ROBERT CHRISTOPHER	reporter.nih.gov
Engaging People Who Use Drugs in Harm Reduction Service Delivery: An Intravention to Reduce Risk of HIV, HCV, Overdose, and Injection-related Infections in Rural Appalachia	NIH	National Institute on Drug Abuse	2024	$1,533,697	September 30, 2024	August 31, 2026	YOUNG, APRIL MARIE	reporter.nih.gov
Neural circuitry and functional significance of extra-SCN pacemakers	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2024	$1,529,842	September 15, 2020	June 30, 2026	YAMAZAKI, SHIN	reporter.nih.gov
Social support, oxytocin and motivation for methamphetamine	NIH	National Institute on Drug Abuse	2021 to 2023	$1,502,424	July 15, 2019	April 30, 2025	BECKER, JILL B.	reporter.nih.gov
Gene Regulation in Memory Circuits as a Consequence of Polysubstance Use	NIH	National Institute on Drug Abuse	2023 to 2025	$1,500,894	August 1, 2023	June 30, 2028	KAUN, KARLA R.	reporter.nih.gov
Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2	NIH	National Institute on Drug Abuse	2025	$1,496,586	April 1, 2025	February 28, 2028	YOUNG, ERICA J	reporter.nih.gov
Short Sleep Duration as a Predictor of Methamphetamine Intake: Role of Orexin Mechanisms	NIH	National Institute on Drug Abuse	2024 to 2025	$1,492,883	July 15, 2024	April 30, 2029	BERRO, LAIS F	reporter.nih.gov
Deep TMS Neuromodulation of Neural Circuits Associated with Stimulant Use Disorder	NIH	National Institute on Drug Abuse	2024	$1,491,755	September 15, 2024	August 31, 2026	PADULA, CLAUDIA B.	reporter.nih.gov
Assessing the role of corticostriatal circuitry in polysubstance use of fentanyl and methamphetamine using rat self-administration models	NIH	National Institute on Drug Abuse	2023 to 2025	$1,475,011	June 15, 2023	April 30, 2028	FERGUSON, SUSAN MARIE	reporter.nih.gov
Molecular Mechanisms of HIV Latency	NIH	National Institute on Drug Abuse	2021	$1,467,490	April 15, 2016	June 30, 2023	VERDIN, ERIC M.	reporter.nih.gov
Methamphetamine Activation of Inflammasome and Altered immunity in HIV (MAIA) Study	NIH	National Institute on Drug Abuse	2024 to 2025	$1,456,335	September 30, 2024	July 31, 2029	PEREIRA RIBEIRO, SUSAN	reporter.nih.gov
Bath Salts: abuse-related and toxic effects	NIH	National Institute on Drug Abuse	2021 to 2024	$1,439,490	April 1, 2015	March 31, 2026	COLLINS, GREGORY THOMAS	reporter.nih.gov
Identification of Biomarkers of CNS injury and resilience related to HIV-1 and Methamphetamine	NIH	National Institute on Drug Abuse	2021 to 2022	$1,427,395	September 15, 2018	June 30, 2025	IUDICELLO, JENNIFER E	reporter.nih.gov
The impact of poly-substance use on the crosstalk between microglia, astrocytes, and neurons that regulates HIV latency	NIH	National Institute on Drug Abuse	2024 to 2025	$1,417,276	May 15, 2024	February 28, 2029	KARN, JONATHAN	reporter.nih.gov
Targeting autophagy to reduce inflammasome-mediated inflammation and immune dysfunction in HIV and methamphetamine use	NIH	National Institute on Drug Abuse	2024 to 2025	$1,416,081	June 1, 2024	March 31, 2029	ZHEN, ANJIE	reporter.nih.gov
Cell type transcriptional mechanisms of polysubstance choice	NIH	National Institute on Drug Abuse	2023 to 2025	$1,376,550	July 1, 2023	May 31, 2028	HAMILTON, PETER JAMES	reporter.nih.gov
Deep Brain Stimulation (DBS) For Severe Treatment Refractory Methamphetamine Use Disorder	NIH	National Institute on Drug Abuse	2022 to 2023	$1,366,011	June 1, 2022	May 31, 2025	SAKAI, JOSEPH T	reporter.nih.gov
A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities	NIH	National Institute on Drug Abuse	2021 to 2022	$1,336,341	February 1, 2022	December 31, 2023	MATUS GARCIA, MARIANA G	reporter.nih.gov
17α-estradiol and sex-differences in HAND with methamphetamine	NIH	National Institute on Drug Abuse	2023 to 2025	$1,333,494	September 1, 2023	July 31, 2028	CHEN, XUESONG	reporter.nih.gov
Dopamine system as reporter of HIV status and inflammation in Meth abusers	NIH	National Institute on Drug Abuse	2021 to 2023	$1,302,264	February 1, 2019	January 31, 2025	MARCONDES, MARIA CECILIA GARIBALDI	reporter.nih.gov
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function	NIH	National Institute on Drug Abuse	2021 to 2022	$1,297,577	July 1, 2018	April 30, 2024	LONDON, EDYTHE DANICK	reporter.nih.gov
Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems with Parental Opioid and Methamphetamine Use	NIH	National Institute on Drug Abuse	2025	$1,261,490	September 15, 2025	May 31, 2030	SALDANA, LISA	reporter.nih.gov
K channel, NLRP3 inflammasome and Meth exacerbation of HAND	NIH	National Institute on Drug Abuse	2021 to 2023	$1,234,632	September 30, 2019	June 30, 2025	XIONG, HUANGUI HANK	reporter.nih.gov
Identification and Regulation of RNA Modification by HIV infection and Methamphetamine	NIH	National Institute on Drug Abuse	2021 to 2022	$1,232,056	April 1, 2018	January 31, 2025	RANA, TARIQ M	reporter.nih.gov
Dissecting the Abuse Liability of Cathinone and Amphetamine Stimulants	NIH	National Institute on Drug Abuse	2023 to 2025	$1,185,000	September 30, 2016	July 31, 2028	TAFFE, MICHAEL A.	reporter.nih.gov
Methamphetamine, HIV integration and latency in the brain	NIH	National Institute on Drug Abuse	2023 to 2024	$1,175,173	September 30, 2023	August 31, 2025	MARCONDES, MARIA CECILIA GARIBALDI	reporter.nih.gov
Inflammasome Activation and Gut-Brain Axis Dysregulation in HIV and Methamphetamine-Associated Depression	NIH	National Institute on Drug Abuse	2024 to 2025	$1,146,614	March 15, 2024	January 31, 2029	TOBOREK, MICHAL	reporter.nih.gov
Targeted CRISPR/Cas Editing to Eliminate SIV CNS Reservoir in Methamphetamine-Exposed Rhesus Macaques on ART	NIH	National Institute on Drug Abuse	2025	$1,144,344	August 15, 2025	May 31, 2030	LING, BINHUA "JULIE"	reporter.nih.gov
Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIV	NIH	National Institute on Drug Abuse	2023 to 2024	$1,142,172	July 1, 2023	June 30, 2025	GASKILL, PETER JESSE	reporter.nih.gov
Extracellular vesicles, meth relapse and sex differences	NIH	National Institute on Drug Abuse	2021 to 2022	$1,120,035	September 30, 2018	June 30, 2024	PENDYALA, GURUDUTT	reporter.nih.gov
Pharmacology of Stimulant Choice	NIH	National Institute on Drug Abuse	2023 to 2025	$1,047,939	April 15, 2023	February 29, 2028	BANKS, MATTHEW L	reporter.nih.gov
An integrated incentive-based treatment to optimize HIV treatment engagement among persons who use methamphetamine	NIH	National Institute on Drug Abuse	2021 to 2025	$1,028,700	May 1, 2021	April 30, 2027	MONTOYA, JESSICA LYNETTE	reporter.nih.gov
Epigenetic regulation of astrocyte-specific NLRP6 inflammasome and PANoptosis in HIV Tat and methamphetamine-mediated neuroinflammation	NIH	National Institute on Drug Abuse	2024 to 2025	$1,023,771	July 1, 2024	April 30, 2029	PERIYASAMY, PALSAMY	reporter.nih.gov
Effects of methamphetamine use on risk behavior, systemic and mucosal inflammation, and sexually transmitted infection (STI)/HIV risk among men who have sex with men	NIH	National Institute on Drug Abuse	2021 to 2025	$1,011,960	July 15, 2021	June 30, 2027	BLAIR, CHERIE SAVINE	reporter.nih.gov
Transgenerational Inheritance of a Cocaine Resistance Phenotype	NIH	National Institute on Drug Abuse	2021 to 2022	$1,009,002	April 1, 2012	January 31, 2023	PIERCE, ROBERT CHRISTOPHER	reporter.nih.gov
Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder	NIH	National Institute on Drug Abuse	2024 to 2025	$989,771	May 15, 2024	March 31, 2029	MCCORVY, JOHN D	reporter.nih.gov
In situ spatial characterization of CNS HIV-host cellular interactions from victims of sudden death	NIH	National Institute on Drug Abuse	2024 to 2025	$983,744	September 30, 2024	July 31, 2027	HENRICH, TIMOTHY JENSEN	reporter.nih.gov
Glutide for Ending Methamphetamine	NIH	National Institute on Drug Abuse	2025	$977,129	September 1, 2025	August 31, 2027	COFFIN, PHILLIP O	reporter.nih.gov
Decoding ensemble dynamics from cortico-amygdalar circuits during social choice	NIH	National Institute of Mental Health	2023 to 2025	$965,142	August 1, 2023	July 31, 2028	ALLSOP, AZA STEPHEN	reporter.nih.gov
Optimization of novel thioesters as a therapeutic strategy for combating opioid overdoses and abuse	NIH	National Institute on Drug Abuse	2021 to 2022	$956,514	September 1, 2020	July 31, 2023	LEWIS, STEPHEN JOHN	reporter.nih.gov
Getting Off: A Theory-based mHealth Intervention for Methamphetamine-using MSM	NIH	National Institute on Drug Abuse	2021 to 2022	$953,199	July 15, 2018	April 30, 2024	REBACK, CATHY J	reporter.nih.gov
Trajectories of socially regulated gene expression, methamphetamine use, and viral load among HIV-positive men who have sex with men (MSM) receiving contingency management	NIH	National Institute on Drug Abuse	2021 to 2025	$947,005	April 1, 2021	March 31, 2026	LI, MICHAEL JONATHAN	reporter.nih.gov
The ION+EMI Study: Intermittent Oral Naltrexone enhanced with an Ecological Momentary Intervention for Methamphetamine-using MSM	NIH	National Institute on Drug Abuse	2021 to 2023	$944,445	September 1, 2021	July 31, 2025	SANTOS, GLENN-MILO	reporter.nih.gov
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease	NIH	National Institute on Drug Abuse	2021	$943,730	August 1, 2018	May 31, 2024	LEE, SULGGI ANGELA	reporter.nih.gov
Molecular Pathways of Innate Immunity and Substance Abuse in NeuroHIV	NIH	National Institute on Drug Abuse	2023 to 2024	$927,683	September 30, 2023	July 31, 2025	INACIO MAMEDE, JOAO FILIPE	reporter.nih.gov
Investigating Parkin-mediated Neuronal Energy Maintenance in Methamphetamine Use Disorder	NIH	National Institute on Drug Abuse	2023 to 2025	$881,915	September 30, 2023	June 30, 2028	MOSZCZYNSKA, ANNA	reporter.nih.gov
Patient Navigator plus Remote mHealth Adherence Support with Incentives: Understanding Criminal Justice Effects	NIH	National Institute on Drug Abuse	2022 to 2023	$841,820	September 30, 2023	September 29, 2024	TSUI, JUDITH	reporter.nih.gov
Cue Reactivity Modulation in MSM with Methamphetamine Use Disorder	NIH	National Institute on Drug Abuse	2023 to 2024	$827,884	September 30, 2023	March 21, 2025	PARVAZ, MUHAMMAD ADEEL	reporter.nih.gov
Short-term Outcome of Stimulant Use Disorder Treatment Trials	NIH	National Institute on Drug Abuse	2022 to 2023	$818,750	August 1, 2022	January 31, 2024	MOJTABAI, RAMIN	reporter.nih.gov
Methamphetamine and Cysteinyl Leukotrienes in HIV Persistence	NIH	National Institute on Drug Abuse	2025	$804,728	June 1, 2025	April 30, 2030	KAUL, MARCUS	reporter.nih.gov
Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2023	$802,521	January 1, 2021	December 31, 2024	MILLER, COURTNEY A	reporter.nih.gov
Methamphetamine, HIV integration and latency in the brain	NIH	National Institute on Drug Abuse	2025	$798,422	September 30, 2023	August 31, 2028	MARCONDES, MARIA CECILIA GARIBALDI	reporter.nih.gov
Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation	NIH	National Institute on Drug Abuse	2021 to 2022	$792,500	April 1, 2018	February 29, 2024	HO, WENZHE	reporter.nih.gov
Interplay between limbic norepinephrine and dopamine circuits in reward and aversion	NIH	National Institute on Drug Abuse	2025	$781,032	August 1, 2025	April 30, 2030	PARK, JINWOO	reporter.nih.gov
Addressing negative social experiences through coping and resilience to reduce methamphetamine use and improve PrEP cascade progression among Latino MSM	NIH	National Institute on Drug Abuse	2022 to 2025	$754,144	September 1, 2022	August 31, 2027	ALGARIN, ANGEL B	reporter.nih.gov
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption	NIH	National Institute on Drug Abuse	2021	$752,263	July 1, 2017	May 31, 2024	BERMAN, JOAN WEINBERGER	reporter.nih.gov
The protective effect of volitional social interaction on drug addiction	NIH	National Institute on Drug Abuse	2021 to 2023	$747,000	May 1, 2021	April 30, 2025	VENNIRO, MARCO	reporter.nih.gov
Role of orexin receptors in the abuse- and sleep-related effects of methamphetamine	NIH	National Institute on Drug Abuse	2022 to 2024	$747,000	August 1, 2020	July 31, 2026	BERRO, LAIS F	reporter.nih.gov
Molecular Pathways of Innate Immunity and Substance Abuse in NeuroHIV	NIH	National Institute on Drug Abuse	2025	$733,223	September 30, 2023	July 31, 2028	I. MAMEDE, JOAO	reporter.nih.gov
Advancing Non-Abstinence Outcomes in the Treatment of Methamphetamine Use Disorder	NIH	National Institute on Drug Abuse	2025	$731,997	September 30, 2025	May 31, 2030	STOOPS, WILLIAM WALTON	reporter.nih.gov
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory	NIH	National Institute on Drug Abuse	2021	$721,617	December 15, 2019	November 30, 2024	MILLER, COURTNEY A	reporter.nih.gov
A longitudinal analysis of methamphetamine use, social relationships, and cognitive function among people living with HIV	NIH	National Institute on Drug Abuse	2021 to 2024	$720,272	September 30, 2021	July 31, 2026	BENDER, ALEXIS ANNE	reporter.nih.gov
The Mechanistic Role of Visual Areas at the Interaction of Social Behavior and Drug Effects in Nonhuman Primates	NIH	National Institute on Drug Abuse	2025	$712,500	September 1, 2025	May 31, 2030	PONCE, CARLOS RAMON	reporter.nih.gov
Cortical Plasticity in Methamphetamine Addiction	NIH	National Institute on Drug Abuse	2021 to 2022	$710,126	September 15, 2012	June 30, 2024	SCOFIELD, MICHAEL DAVID	reporter.nih.gov
Genetic Factors Underlying Risk for Methamphetamine Intake and Associated Traits	NIH	National Institute on Drug Abuse	2021 to 2022	$693,986	September 30, 2018	July 31, 2024	PHILLIPS, TAMARA J.	reporter.nih.gov
Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIV	NIH	National Institute on Drug Abuse	2025	$677,147	July 1, 2023	June 30, 2028	GASKILL, PETER JESSE	reporter.nih.gov
Development of selective cannabinoid receptor 2 agonists for treatment of addiction	NIH	National Institute of Neurological Disorders and Stroke	2022	$661,980	April 19, 2022	March 31, 2023	SHAMLOO, MEHRDAD	reporter.nih.gov
RESTORE (Recovery and Engagement for STimulant users On Re-entry)	NIH	National Institute on Drug Abuse	2025	$660,104	August 15, 2025	July 31, 2027	NIJHAWAN, ANK ELISABETH	reporter.nih.gov
Advancing Troriluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study	NIH	National Institute on Drug Abuse	2025	$634,048	April 15, 2025	February 28, 2029	STOOPS, WILLIAM WALTON	reporter.nih.gov
Data Mining and Functional Validation of SCORCH Datasets	NIH	National Institute on Drug Abuse	2025	$608,652	September 1, 2025	May 31, 2030	SANNA, PIETRO P	reporter.nih.gov
Midcareer K24 Award for Mentoring and Patient-Oriented Research	NIH	National Institute on Drug Abuse	2023 to 2025	$602,500	February 1, 2023	January 31, 2028	COFFIN, PHILLIP O	reporter.nih.gov
Leveraging Networks, Epidemiology, and Epidemic Modeling: Creative Approaches for HIV Elimination	NIH	National Institute on Drug Abuse	2021 to 2023	$568,491	August 15, 2019	July 31, 2025	SKAATHUN, BRITT	reporter.nih.gov
Mentoring clinician scientists in patient-oriented substance use disorder research	NIH	National Institute on Drug Abuse	2023 to 2025	$554,316	June 15, 2023	May 31, 2028	SAKAI, JOSEPH T	reporter.nih.gov
Chemokine Receptor Antagonists (CRAs): Characterization in Preclinical Models of Methamphetamine Use Disorder	NIH	National Institute on Drug Abuse	2025	$552,629	July 1, 2025	March 31, 2030	RAWLS, SCOTT M.	reporter.nih.gov
Impact of miRNAs on adult neurogenesis following exposure to methamphetamine and HIV-1 Infection	NIH	National Institute on Drug Abuse	2024 to 2025	$529,515	April 1, 2024	March 31, 2027	PARK, MIN SEON	reporter.nih.gov
Local labor market contexts and substance use in young and middle adulthood: Using agent-based modeling to guide substance use prevention strategies	NIH	National Institute on Drug Abuse	2023 to 2025	$524,091	July 1, 2023	June 30, 2028	OH, SEHUN	reporter.nih.gov
Methamphetamine-Alcohol Interactions and Mechanisms of Augmented Toxicity to Brain and Peripheral Organs	NIH	National Institute on Drug Abuse	2021	$506,780	August 1, 2017	May 31, 2023	ATWOOD, BRADY	reporter.nih.gov
Role of PCIF1 in Regulating Host-HIV interactions	NIH	National Institute of Allergy and Infectious Diseases	2024	$502,861	July 24, 2024	June 30, 2025	RANA, TARIQ M	reporter.nih.gov
Development of a Behavioral Economic Intervention to Reduce HIV Risk Behaviors	NIH	National Institute on Drug Abuse	2024 to 2025	$499,415	September 15, 2024	August 31, 2027	OKAFOR, CHUKWUEMEKA NKEMAKONAM	reporter.nih.gov
Dopamine Neuronal Microcircuits Controlling Methamphetamine Seeking Behavior	NIH	National Institute on Drug Abuse	2024 to 2025	$498,000	July 19, 2021	November 30, 2026	DOMINGUEZ LOPEZ, SERGIO	reporter.nih.gov
Hypocretin contributions to compulsive methamphetamine self-administration in rats	NIH	National Institute on Drug Abuse	2021 to 2022	$497,859	April 1, 2017	July 31, 2024	SCHMEICHEL, BROOKE E	reporter.nih.gov
Prevention of Methamphetamine Use among Postpartum Women (PROMPT)	NIH	National Institute on Drug Abuse	2021 to 2022	$496,125	June 1, 2022	May 31, 2024	SMID, MARCELA	reporter.nih.gov
Interactive effects of Meth, HIV and cART on astrocyte/neuron function	NIH	National Institute on Drug Abuse	2021	$495,905	August 15, 2017	June 30, 2024	HU, XIU-TI	reporter.nih.gov
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users	NIH	National Institute on Drug Abuse	2021	$488,953	September 15, 2017	January 31, 2023	RENSHAW, PERRY FRANKLIN	reporter.nih.gov
Exploring the role of reactive astrocytes in brain inflammation using a novel combinatorial strategy	NIH	National Institute on Drug Abuse	2021	$487,142	August 1, 2019	May 31, 2023	FIACCO, TODD A	reporter.nih.gov
Supporting data-driven decision-making to support substance use service expansion policies and to prevent overdoses	NIH	National Institute on Drug Abuse	2023	$486,685	September 1, 2023	August 31, 2024	CRUDEN, GRACELYN	reporter.nih.gov
Cocaine induces production of infectious large extracellular vesicles (IEV) and regulates neuro-inflammation	NIH	National Institute on Drug Abuse	2021	$462,445	July 15, 2020	June 30, 2022	PRASAD, ANIL	reporter.nih.gov
Modulating the pharmacodynamics of methamphetamine and fentanyl co-use via hypocretin pathways	NIH	National Institute on Drug Abuse	2025	$457,701	August 1, 2025	April 30, 2030	SCHMEICHEL, BROOKE E	reporter.nih.gov
Airway compromise and skeletal muscle rigidity as toxicity contributors in synthetic opioid and methamphetamine co-administered rats	NIH	National Institute on Drug Abuse	2024 to 2025	$452,603	September 15, 2024	August 31, 2026	COTTEN, JOSEPH F	reporter.nih.gov
Functional validation of a role for the candidate gene Ctr9 in psychostimulant action	NIH	National Institute on Drug Abuse	2022 to 2023	$439,725	September 1, 2022	August 31, 2025	JAVITCH, JONATHAN A	reporter.nih.gov
Influence of synthetic sex hormones on methamphetamine effects and self-administration in women	NIH	National Institute on Drug Abuse	2023 to 2024	$439,725	May 15, 2023	April 30, 2026	CHILDS, EMMA	reporter.nih.gov
Deconvoluting Dopaminergic Neuronal-Glial Interactions in the Striatum	NIH	National Institute on Drug Abuse	2025	$439,180	September 1, 2025	August 31, 2027	BROWN, AMANDA MARIA	reporter.nih.gov
Macrocyclic Arenes as Sequestrants for Drugs of Abuse	NIH	National Institute on Drug Abuse	2024 to 2025	$425,976	June 15, 2024	May 31, 2027	ISAACS, LYLE D	reporter.nih.gov
Psychostimulants, Attention Deficit and Basal Ganglia Disorders	NIH	National Institute on Drug Abuse	2022 to 2023	$422,979	September 1, 2022	August 31, 2025	FLECKENSTEIN, ANNETTE	reporter.nih.gov
Optimizing long-acting injectable PrEP strategies for sexual minority men who use methamphetamine	NIH	National Institute on Drug Abuse	2024	$420,319	September 30, 2024	September 29, 2026	GROV, CHRISTIAN	reporter.nih.gov
Validation of a survey tool to evaluate patient-reported outcomes for new medications to treat methamphetamine use disorder: The PROMT Survey	NIH	National Institute on Drug Abuse	2024 to 2025	$415,218	September 30, 2024	August 31, 2027	PRO, GEORGE	reporter.nih.gov
Role of Perineuronal Nets in Methamphetamine-Induced Hypofrontality and Cognitive Deficits	NIH	National Institute on Drug Abuse	2023 to 2024	$412,700	June 1, 2023	May 31, 2026	LAVIN, ANTONIETA	reporter.nih.gov
Immunotherapeutic Targeting CD74 as a Treatment for Stimulant Use Disorder	NIH	National Institute on Drug Abuse	2024	$405,334	June 15, 2024	May 31, 2026	SHIRLEY, RENEE LYNN	reporter.nih.gov
Prevention of HIV and drug abuse-induced brain pathology by targeting mitochondria	NIH	National Institute on Drug Abuse	2021	$404,557	July 1, 2017	May 31, 2023	TOBOREK, MICHAL	reporter.nih.gov
Short-term Outcome of Stimulant Use Disorder Treatment Trials	NIH	National Institute on Drug Abuse	2024	$403,206	July 1, 2024	June 30, 2026	MOJTABAI, RAMIN	reporter.nih.gov
Neural mechanisms of sex differences in vulnerability to the effects of adolescent methamphetamine exposure	NIH	National Institute on Drug Abuse	2022 to 2023	$397,882	August 1, 2022	July 31, 2025	GULLEY, JOSHUA M	reporter.nih.gov
Multilevel Influences on Drug Use and HIV-Related Outcomes Among Men	NIH	National Institute on Drug Abuse	2024 to 2025	$390,687	March 1, 2024	February 28, 2029	MOODY, RAYMOND LEE	reporter.nih.gov
A novel phase and spectroscopic imaging technique to evaluate mitochondrial dynamics	NIH	National Institute on Drug Abuse	2021	$373,844	February 1, 2019	January 31, 2024	KHMALADZE, ALEXANDER	reporter.nih.gov
CHAMPION - Combining HIV And Stimulant Prevention and Treatment Interventions Optimized for HIV-Negative MSM	NIH	National Institute on Drug Abuse	2024 to 2025	$354,921	August 15, 2024	July 31, 2027	TSUYUKI, KIYOMI	reporter.nih.gov
Brain Age of People with HIV and History of Methamphetamine Use	NIH	National Institute on Drug Abuse	2024 to 2025	$339,383	May 15, 2024	April 30, 2029	LOBO, JUDITH DIANE	reporter.nih.gov
Molecular Mechanisms of Susceptibility to Drug Use	NIH	National Institute on Drug Abuse	2021 to 2023	$337,147	January 4, 2021	September 1, 2023	GROMAN, STEPHANIE MARY	reporter.nih.gov
Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder	NIH	National Institute on Drug Abuse	2024	$320,000	May 1, 2024	April 30, 2026	VARADHACHARY, ATUL	reporter.nih.gov
Stimulant Use Recovery Via Immersive Virtual Environments (SURVIVE)	NIH	National Institute on Drug Abuse	2024	$319,988	September 30, 2024	September 29, 2025	BRACKEN, BETHANY K	reporter.nih.gov
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment of methamphetamine use disorder	NIH	National Institute on Drug Abuse	2023	$319,983	May 15, 2023	May 14, 2025	CIPPITELLI, ANDREA	reporter.nih.gov
An oral therapeutic to treat intoxication by prescription and illicit stimulants	NIH	National Institute on Drug Abuse	2022	$319,946	September 30, 2022	March 31, 2023	LI, XINHUA	reporter.nih.gov
A novel therapeutic approach for treatment of acute intoxication by co-use of opioids and stimulants	NIH	National Institute on Drug Abuse	2022	$319,695	July 1, 2022	December 31, 2022	LI, XINHUA	reporter.nih.gov
Demonstration of a Digital Care Program for Methamphetamine Use Disorder	NIH	National Institute on Drug Abuse	2021	$309,360	September 30, 2021	September 29, 2022	MUHLNER, KRISTIN	reporter.nih.gov
Impact of cannabidiol on HIV infection and methamphetamine abuse associated neuroinflammation	NIH	National Institute on Drug Abuse	2024 to 2025	$307,000	April 1, 2024	March 31, 2027	CHAND, SUBHASH	reporter.nih.gov
Molecular Mechanisms of Susceptibility to Drug Use.	NIH	National Institute on Drug Abuse	2023 to 2024	$301,581	January 4, 2021	June 30, 2025	GROMAN, STEPHANIE MARY	reporter.nih.gov
Impact of adolescent nicotine exposure on methamphetamine self-administration in female rats	NIH	National Institute of General Medical Sciences	2024 to 2025	$294,000	May 15, 2024	April 30, 2028	CRAWFORD, CYNTHIA A.	reporter.nih.gov
Disrupting Social Determinants of Health to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions	NIH	National Institute on Drug Abuse	2022	$276,961	September 30, 2022	August 31, 2023	SALDANA, LISA	reporter.nih.gov
Dopamine Neuronal Microcircuits Controlling Methamphetamine Seeking Behavior	NIH	National Institute on Drug Abuse	2021 to 2022	$272,952	July 19, 2021	August 31, 2023	DOMINGUEZ LOPEZ, SERGIO	reporter.nih.gov
Preventing alcohol seeking with a nonmuscle myosin II inhibitor under clinical development	NIH	National Institute on Alcohol Abuse and Alcoholism	2021	$267,975	May 15, 2021	April 1, 2022	MILLER, COURTNEY A	reporter.nih.gov
Xylazine effects on methamphetamine-induced behavioral alterations in rats	NIH	National Institute on Drug Abuse	2025	$237,750	April 15, 2025	March 31, 2027	RAWLS, SCOTT M.	reporter.nih.gov
Regulator of G protein Signaling-12 (RGS12) as a target for SUD therapeutics development	NIH	National Institute on Drug Abuse	2021	$222,568	December 1, 2020	November 30, 2022	SETOLA, VINCENT	reporter.nih.gov
Tailoring Delivery of LongActing PrEP for Cisgender (MSM) who Use Methamphetamine	NIH	National Institute on Drug Abuse	2024	$220,370	September 1, 2023	August 31, 2025	MCMAHAN, VANESSA	reporter.nih.gov
L-type Calcium Channel SNP rs1006737: characterizing the genetic risks in MUD (Methamphetamine Use Disorder)	NIH	National Institute on Drug Abuse	2023	$218,250	September 30, 2023	September 29, 2025	ANDRES, MARILOU A.	reporter.nih.gov
Molecular mechanisms of incubation of methamphetamine craving	NIH	National Institute on Drug Abuse	2024	$211,211	February 1, 2024	January 31, 2025	SWINFORD-JACKSON, SARAH E.	reporter.nih.gov
ACCOMPLISH (Applied Coaching of COMPutational Learners In Substance use and HIV) Mentoring Program	NIH	National Institute on Drug Abuse	2025	$206,180	September 1, 2025	August 31, 2030	LEE, SULGGI ANGELA	reporter.nih.gov
Investigating the role of microglia molecular rhythms in the nucleus accumbens in OUD	NIH	National Institute on Drug Abuse	2024 to 2025	$199,507	September 15, 2022	August 31, 2028	VILCA, SAMARA JO	reporter.nih.gov
Trajectories of social isolation and loneliness among older adults living with HIV who use methamphetamine	NIH	National Institute on Drug Abuse	2025	$198,854	August 1, 2025	July 31, 2027	HAN, BENJAMIN HYUN	reporter.nih.gov
Effect of Methamphetamine and/or HIV on Human iPSCs-derived microglia and Neuron	NIH	National Institute on Drug Abuse	2021	$198,125	July 15, 2020	June 30, 2023	HO, WENZHE	reporter.nih.gov
Preventing alcohol seeking with a nonmuscle myosin II inhibitor under clinical development	NIH	National Institute on Alcohol Abuse and Alcoholism	2022	$197,731	May 15, 2021	April 30, 2024	MILLER, COURTNEY A	reporter.nih.gov
High-Throughput Whole-Brain Screening for Drug-Induced Chemical Imbalance in the Brain	NIH	National Institute on Drug Abuse	2021	$197,344	April 1, 2020	March 31, 2023	SPITZER, NICHOLAS CANADAY	reporter.nih.gov
DAT-Psychostimulant mediated dopamine release increases macrophage IL-1beta production through NF-kB activation and inflammasome priming	NIH	National Institute on Drug Abuse	2021	$195,625	April 1, 2020	March 31, 2023	GASKILL, PETER JESSE	reporter.nih.gov
Molecular mechanisms of incubation of methamphetamine craving	NIH	National Institute on Drug Abuse	2025	$193,446	April 3, 2025	January 31, 2029	SWINFORD-JACKSON, SARAH E.	reporter.nih.gov
Tailoring Delivery of LongActing PrEP for Cisgender (MSM) who Use Methamphetamine	NIH	National Institute on Drug Abuse	2023	$183,080	September 15, 2023	August 31, 2024	MCMAHAN, VANESSA	reporter.nih.gov
Role of parasubthalamic astrocytic dysfunction in alcohol use disorder	NIH	National Institute on Alcohol Abuse and Alcoholism	2024 to 2025	$181,753	February 1, 2023	January 31, 2028	WHITE, ALLISON	reporter.nih.gov
Predicting craving and relapse using neurobehavioral markers of goals and habits in opioid use disorder	NIH	National Institute on Drug Abuse	2025	$159,615	July 15, 2025	June 30, 2027	CECELI, AHMET OGUZ	reporter.nih.gov
Methamphetamine and Antiretroviral Therapy Impact Macrophage Functions and Macroautophagy: Implications for HIV Neuropathogenesis	NIH	National Institute on Drug Abuse	2021 to 2023	$150,425	August 1, 2021	May 23, 2024	BARBARO, JOHN M	reporter.nih.gov
Methocinnamox (MCAM): A novel ÃÂµ-opioid receptor antagonist for opioid use disorders	NIH	National Institute on Drug Abuse	2022	$147,995	September 30, 2019	August 31, 2022	FRANCE, CHARLES P	reporter.nih.gov
Characterization of Polysubstance Use: Combined Fentanyl and Methamphetamine	NIH	National Institute on Drug Abuse	2023 to 2025	$146,206	February 1, 2023	January 31, 2027	DAWES, MONICA H	reporter.nih.gov
Behavioral compensation in goal-directed action: Long term effects of voluntary methamphetamine taking versus passive exposure	NIH	National Institute on Drug Abuse	2023 to 2024	$142,383	September 1, 2023	August 31, 2025	PICKENS, CHARLES LEE	reporter.nih.gov
Investigating anti-neuroinflammatory therapeutics for polysubstance use disorders	NIH	National Institute of General Medical Sciences	2025	$142,100	September 1, 2025	August 31, 2029	SCHMEICHEL, BROOKE E	reporter.nih.gov
Friendship Bench for Women Who Use Methamphetamine in Vietnam	NIH	Fogarty International Center	2024 to 2025	$141,853	September 16, 2024	August 31, 2029	NGUYEN, TRANG	reporter.nih.gov
Chronic methamphetamine-induced catecholaminergic degeneration and cognitive dysfunction	NIH	National Institute on Drug Abuse	2022 to 2024	$136,920	January 14, 2022	January 13, 2025	PILSKI, ALEXANDER N	reporter.nih.gov
Characteristics and outcomes for hospitalized patients with methamphetamine and opioid co-use: Identifying opportunities for hospital-based addiction services tailored to co-use	NIH	National Institute on Drug Abuse	2023 to 2025	$135,931	March 1, 2023	February 28, 2027	SHEARER, RILEY	reporter.nih.gov
Role of orexin receptors in the abuse- and sleep-related effects of methamphetamine	NIH	National Institute on Drug Abuse	2021	$126,997	August 1, 2020	July 31, 2022	BERRO, LAIS F	reporter.nih.gov
Neurochemical mechanisms governing footshock-induced suppression of methamphetamine intake	NIH	National Institute on Drug Abuse	2022	$120,750	June 15, 2022	May 31, 2025	JOB, MARTIN O	reporter.nih.gov
Determinants of transitioning from injecting to smoking fentanyl and methamphetamine and implications for harm reduction implementation	NIH	National Institute on Drug Abuse	2024 to 2025	$107,862	September 1, 2024	August 31, 2026	EGER, WILLIAM HENRY	reporter.nih.gov
Role of sleep disruption in cognitive impairment associated with methamphetamine use	NIH	National Institute on Drug Abuse	2024 to 2025	$98,512	April 2, 2024	April 1, 2027	BORGATTI, DANIEL	reporter.nih.gov
Role of Lateral Habenula- Dorsal Raphe Circuit on MA-Induced Aversion	NIH	National Institute on Drug Abuse	2023 to 2024	$96,668	February 16, 2023	February 15, 2025	RIOS, SAMANTHA	reporter.nih.gov
Exploration of the unique neurobehavioral profile of sequential opioid-stimulant polysubstance use disorders	NIH	National Institute on Drug Abuse	2024 to 2025	$91,074	March 1, 2024	February 28, 2027	SAAVEDRA, SARA	reporter.nih.gov
Trends in Associations between Maternal Methamphetamine Use and Congenital Syphilis in Los Angeles County, 2011 through 2020	NIH	National Institute on Drug Abuse	2023 to 2025	$86,896	December 1, 2023	November 30, 2025	PARK, EUNHEE	reporter.nih.gov
Simulation Modeling to Support the Public Health Response to the Opioid Crisis in North America	NIH	National Institute on Drug Abuse	2021 to 2023	$74,115	June 1, 2021	July 31, 2024	SCHACKMAN, BRUCE R	reporter.nih.gov
Exploring synaptic actin-myosin dynamics with super resolution microscopy	NIH	National Institute of Neurological Disorders and Stroke	2024 to 2025	$72,512	September 1, 2024	August 31, 2026	REED, SHAYNA JORDAN	reporter.nih.gov
The ER-mitochondria interface in astrocytes during METH exposure and HIV-1 infection	NIH	National Institute on Drug Abuse	2021 to 2022	$57,855	May 1, 2021	December 4, 2022	PROULX, JESSICA MICHELLE	reporter.nih.gov
Using Multivariate Mixture Models to Study Polysubstance Use with Methamphetamine in Nationally Representative and Population Samples	NIH	National Institute on Drug Abuse	2025	$53,961	June 1, 2025	May 31, 2026	ROGERS, JEFFREY	reporter.nih.gov
Methamphetamine and HIV status modulate the neural dynamics underlying executive dysfunction and emotion dysregulation	NIH	National Institute on Drug Abuse	2023	$53,460	August 1, 2023	May 31, 2024	SCHANTELL, MIKKI	reporter.nih.gov
Polysubstance use and mental health outcomes after substance abuse treatment among community-based men of color who have sex with men in Los Angeles living with and without HIV	NIH	National Institute on Drug Abuse	2023	$52,499	September 30, 2023	August 31, 2024	KOERBER, JULIA JAN	reporter.nih.gov
The effect of opioids, stimulants, and the simultaneous use of both on the hepatitis C virus (HCV) cascade of care in rural communities in the United States	NIH	National Institute on Drug Abuse	2022 to 2023	$51,995	May 3, 2022	May 7, 2023	ESTADT, ANGELA T	reporter.nih.gov
Altered Oscillatory Dynamics in People with HIV and Methamphetamine Use Disorder	NIH	National Institute on Drug Abuse	2022 to 2023	$51,861	March 9, 2022	July 31, 2023	SCHANTELL, MIKKI	reporter.nih.gov
Substance Use Modeling Consortium Workshop to Support the Public Health Response to the Overdose Crisis in North America	NIH	National Institute on Drug Abuse	2024 to 2025	$49,812	June 1, 2021	July 31, 2029	LINAS, BENJAMIN P.	reporter.nih.gov
Investigation of Novel Drug Targets for Stimulant Use Disorder	NIH	National Institute of Neurological Disorders and Stroke	2023	$48,694	February 1, 2023	December 8, 2023	WHITE, ALLISON	reporter.nih.gov
Investigating the Role of Microglia in Methamphetamine Use Disorder	NIH	National Institute of Neurological Disorders and Stroke	2022	$47,752	September 15, 2022	September 14, 2023	VILCA, SAMARA JO	reporter.nih.gov
The role of VMAT-2 in mediating the impact of HIV-1 protein Tat and methamphetamine on dopamine neurotransmission and behavior	NIH	National Institute on Drug Abuse	2022	$38,708	January 1, 2023	December 31, 2023	DAVIS, SARAH ELIZABETH	reporter.nih.gov
Effects of Neurotensin on VTA Neuron Physiology and Methamphetamine Use	NIH	National Institute on Drug Abuse	2025	$38,696	August 1, 2025	July 31, 2028	LITER, LACI RAI	reporter.nih.gov
Regulation of Methamphetamine-Induced Behaviors by the Neurotensin Receptor 1	NIH	National Institute on Drug Abuse	2025	$37,062	April 1, 2025	March 31, 2028	MOORE, MADELYN	reporter.nih.gov
Modeling the impact of hospital-based addiction consult services on post-discharge mortality	NIH	National Institute on Drug Abuse	2021	$36,347	December 28, 2020	June 30, 2021	KING, CAROLINE	reporter.nih.gov
Effect of Drugs of Abuse on CNS HIV-1 Reservoirs and Neuropathogenesis	NIH	National Institute on Drug Abuse	2021	$9,504	September 1, 2016	July 31, 2022	PRASAD, VINAYAKA R.	reporter.nih.gov
Cannabinoid type 2 receptors as a therapeutic target for substance use disorders	NIH	National Institute on Drug Abuse	2023	$8,368	February 1, 2023	February 20, 2023	CAREY IV, LAWRENCE MICHAEL	reporter.nih.gov
Dopamine neuronal microcircuits controlling methamphetamine seeking behavior	NIH	National Institute on Drug Abuse	2021	$6,470	May 1, 2020	July 2, 2021	DOMINGUEZ LOPEZ, SERGIO	reporter.nih.gov

Organizations

Organization	Place	NIH awards	NIH amount	NSF amount
Ut Southwestern Medical Center	Dallas, TX	3	$45.6 million	$0
Intervexion Therapeutics, LLC	Little Rock, AR	4	$34.6 million	$0
University of Miami School of Medicine	Coral Gables, FL	7	$32.5 million	$0
Clear Scientific, LLC	Cambridge, MA	4	$20.7 million	$0
University of California, San Diego	La Jolla, CA	14	$16.4 million	$0
Johns Hopkins University	Baltimore, MD	4	$15.5 million	$0
Yale University	New Haven, CT	3	$12.8 million	$0
Scripps Research Institute, the	La Jolla, CA	5	$12.1 million	$0
Graduate School of Public Health and Health Policy	New York, NY	3	$10.8 million	$0
University of California, San Francisco	San Francisco, CA	7	$10.6 million	$0
University of Washington	Seattle, WA	5	$10.2 million	$0
Phoenix Pharmalabs, Inc.	Woodscross, UT	2	$9 million	$0
Oregon Health & Science University	Portland, OR	6	$8.9 million	$0
University of Chicago	Chicago, IL	4	$7.8 million	$0
University of Kentucky	Lexington, KY	5	$7.5 million	$0
Biocorrx Pharmaceuticals INC	Anaheim, CA	1	$7.4 million	$0
Chestnut Health Systems, Inc.	Bloomington, IL	4	$6.8 million	$0
Emory University	Atlanta, GA	4	$6.7 million	$0
Public Health Foundation Enterprises	City Of Industry, CA	4	$6.6 million	$0
Sanford Burnham Prebys Medical Discovery Institute	La Jolla, CA	1	$6.4 million	$0
University of Nebraska Medical Center	Omaha, NE	5	$5.8 million	$0
Hager Biosciences, LLC	Bethlehem, PA	1	$5.6 million	$0
Simon Fraser University	Burnaby	1	$5.3 million	$0
University of Florida	Gainesville, FL	5	$4.8 million	$0
University of California Los Angeles	Los Angeles, CA	6	$4.8 million	$0
Case Western Reserve University	Cleveland, OH	3	$4.7 million	$0
Myosin Therapeutics Inc.	Jupiter, FL	2	$4.7 million	$0
Research Triangle Institute	Research Triangle Park, NC	2	$4.6 million	$0
Mclean Hospital	Belmont, MA	2	$4.5 million	$0
Rush University Medical Center	Chicago, IL	4	$4.3 million	$0
Temple Univ of the Commonwealth	Philadelphia, PA	5	$4.3 million	$0
University of California-Riverside	Riverside, CA	3	$3.8 million	$0
Stanford University	Stanford, CA	3	$3.8 million	$0
Virogenomics Biodevelopment, Inc.	Tigard, OR	2	$3.7 million	$0
University of Pennsylvania	Philadelphia, PA	1	$3.7 million	$0
University of Colorado Denver	Aurora, CO	3	$3.6 million	$0
University of Maryland Baltimore	Baltimore, MD	3	$3.5 million	$0
San Diego Biomedical Research Institute	San Diego, CA	3	$3.3 million	$0
SUNY at Buffalo	Amherst, NY	3	$3.2 million	$0
University of Rochester	Rochester, NY	1	$3.1 million	$0
Medical University of South Carolina	Charleston, SC	3	$3 million	$0
Evon Medics, LLC	Elkridge, MD	1	$2.9 million	$0
Northwestern University at Chicago	Chicago, IL	1	$2.6 million	$0
Albert Einstein College of Medicine	Bronx, NY	4	$2.6 million	$0
University of Minnesota	Minneapolis, MN	5	$2.6 million	$0
University of Mississippi Med CTR	Jackson, MS	4	$2.5 million	$0
Virginia Commonwealth University	Richmond, VA	2	$2.4 million	$0
Cincinnati Childrens Hosp Med CTR	Cincinnati, OH	1	$2.4 million	$0
Exqor Technologies, Inc.	Boston, MA	1	$2.4 million	$0
University of Texas HLTH Science Center	San Antonio, TX	4	$2.1 million	$0
New York University School of Medicine	New York, NY	1	$2.1 million	$0
Drexel University	Philadelphia, PA	3	$2 million	$0
University of South Carolina at Columbia	Columbia, SC	2	$2 million	$0
Hanoi Medical University	Hanoi	2	$2 million	$0
Florida International University	Miami, FL	1	$1.9 million	$0
Rutgers Biomedical and Health Sciences	Newark, NJ	2	$1.8 million	$0
Arborsense, Inc.	Ann Arbor, MI	1	$1.7 million	$0
University of Michigan at Ann Arbor	Ann Arbor, MI	1	$1.5 million	$0
Brown University	Providence, RI	1	$1.5 million	$0
Buck Institute for Research on Aging	Novato, CA	1	$1.5 million	$0
University of Utah	Salt Lake City, UT	3	$1.4 million	$0
Biobot Analytics, Inc.	Somerville, MA	1	$1.3 million	$0
University of North Dakota Main Campus	Grand Forks, ND	1	$1.3 million	$0
Texas Biomedical Research Institute	San Antonio, TX	1	$1.1 million	$0
East Tennessee State University	Johnson City, TN	3	$1.1 million	$0
Rbhs-Robert Wood Johnson Medical School	Piscataway, NJ	1	$1 million	$0
Medical College of Wisconsin	Milwaukee, WI	1	$989,771	$0
Scripps Florida	Jupiter, FL	2	$989,592	$0
Icahn School of Medicine at Mount Sinai	New York, NY	2	$987,499	$0
Friends Research Institute, Inc.	Baltimore, MD	1	$953,199	$0
Wayne State University	Detroit, MI	1	$881,915	$0
Arizona State University	Scottsdale, AZ	1	$754,144	$0
Harvard Medical School	Boston, MA	1	$712,500	$0
San Francisco Department of Public Health	San Francisco, CA	1	$602,500	$0
Ohio State University	Columbus, OH	2	$576,086	$0
Indiana University Indianapolis	Indianapolis, IN	1	$506,780	$0
Beth Israel Deaconess Medical Center	Boston, MA	1	$462,445	$0
Massachusetts General Hospital	Boston, MA	1	$452,603	$0
New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, INC	New York, NY	1	$439,725	$0
University of Illinois at Chicago	Chicago, IL	1	$439,725	$0
University of Maryland, College Park	College Park, MD	1	$425,976	$0
Univ of Arkansas for Med Scis	Little Rock, AR	1	$415,218	$0
Tulane University of Louisiana	New Orleans, LA	1	$403,206	$0
University of Illinois at Urbana-Champaign	Urbana, IL	1	$397,882	$0
University of Connecticut	Storrs, CT	1	$390,687	$0
SUNY at Albany	Albany, NY	1	$373,844	$0
Fannin Partners, LLC	Houston, TX	1	$320,000	$0
Charles River Analytics, Inc.	Cambridge, MA	1	$319,988	$0
Affect Therapeutics, Inc.	New York, NY	1	$309,360	$0
University Enterprises Corporation at CSUSB	San Bernardino, CA	1	$294,000	$0
Oregon Social Learning Center, Inc.	Eugene, OR	1	$276,961	$0
West Virginia University Research Corporation	Morgantown, WV	2	$271,262	$0
Harvard Pilgrim Health Care, Inc.	Canton, MA	1	$220,370	$0
University of Hawaii	Honolulu, HI	1	$218,250	$0
Univ of Massachusetts Med SCH Worcester	Worcester, MA	1	$199,507	$0
Texas A&M University	College Station, TX	1	$193,446	$0
Wake Forest University Health Sciences	Winston-Salem, NC	1	$146,206	$0
Kansas State University	Manhattan, KS	1	$142,383	$0
Rowan University	Glassboro, NJ	1	$120,750	$0
Father Flanagan's Boys' Home	Boys Town, NE	2	$105,321	$0

Funding by fiscal year

Fiscal year	NIH awards	NIH amount	NSF amount
2025	118	$87,595,154	$0
2024	125	$93,816,147	$0
2023	114	$87,075,512	$0
2022	104	$92,347,938	$0
2021	85	$79,541,862	$0

Open federal funding opportunities

From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.

Open opportunity	Number	Agency	Listing	Closes	Award ceiling	Why it matches
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)	PA-24-254	NIH		July 12, 2027	Not listed	Notice number printed on 2 awards here
NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)	PA-24-194	NIH		May 7, 2027	Not listed	Notice number printed on 1 award here
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)	RFA-DA-25-060	NIH		March 5, 2027	$1.5 million	Notice number printed on 1 award here
Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)	PA-24-188	NIH		May 7, 2027	Not listed	Notice number printed on 1 award here
NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)	PAR-24-089	NIH	93.279	November 13, 2026	$750,000	Same assistance listing 93.279 as 224 awards here
Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)	PAR-25-370	NIH	93.279	November 16, 2026	$50,000	Same assistance listing 93.279 as 224 awards here
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)	PAR-25-369	NIH	93.279	November 18, 2026	Not listed	Same assistance listing 93.279 as 224 awards here
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)	PAR-25-371	NIH	93.279	November 18, 2026	Not listed	Same assistance listing 93.279 as 224 awards here
Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)	PA-23-317	NIH	93.279	November 24, 2026	Not listed	Same assistance listing 93.279 as 224 awards here
Emerging Global Leader Award (K43 Independent Clinical Trial Required)	PAR-24-295	NIH	93.279	December 3, 2026	Not listed	Same assistance listing 93.279 as 224 awards here
Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)	PAR-24-296	NIH	93.279	December 3, 2026	Not listed	Same assistance listing 93.279 as 224 awards here
NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)	RFA-OD-24-011	NIH	93.279	December 4, 2026	Not listed	Same assistance listing 93.279 as 224 awards here
Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)	PAR-27-039	NIH	93.279	January 5, 2027	Not listed	Same assistance listing 93.279 as 224 awards here
Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)	PAR-27-040	NIH	93.279	January 5, 2027	Not listed	Same assistance listing 93.279 as 224 awards here
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)	PAR-24-214	NIH	93.279	January 7, 2027	$375,000	Same assistance listing 93.279 as 224 awards here
Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)	PAR-25-378	NIH	93.279	January 7, 2027	Not listed	Same assistance listing 93.279 as 224 awards here
Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)	PAR-25-379	NIH	93.279	January 7, 2027	Not listed	Same assistance listing 93.279 as 224 awards here
HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)	RFA-DA-28-011	NIH	93.279	January 26, 2027	Not listed	Same assistance listing 93.279 as 224 awards here
HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (U2C Clinical Trial Not Allowed)	RFA-DA-28-012	NIH	93.279	January 26, 2027	Not listed	Same assistance listing 93.279 as 224 awards here
Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed)	PAR-24-268	NIH	93.279	January 27, 2027	$500,000	Same assistance listing 93.279 as 224 awards here

Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.